Your browser doesn't support javascript.
loading
Functional G-CSF pathways in t(8;21) leukemic cells allow for differentiation induction and degradation of AML1-ETO.
Da Silva, N; Meyer-Monard, S; Menot, M L; Parrado, A; Lebel, A; Balitrand, N; Fenaux, P; Micléa, J M; Rousselot, P; Degos, L; Dombret, H; Chomienne, C.
Affiliation
  • Da Silva N; Laboratoire de Biologie Cellulaire Hématopoïétique (LBCH), INSERM E 00-03, et EA 316 Université Paris 7, Hôpital Saint-Louis, 1 Avenue Claude Vellefaux, 75754 Paris Cedex 10, France. lbch@chu.stlouis.fr
Hematol J ; 1(5): 316-28, 2000.
Article in En | MEDLINE | ID: mdl-11920209
ABSTRACT

INTRODUCTION:

Efficacy of differentiating agents requires that their specific cellular targets are still expressed and functional in the leukemic cells. One hypothesis to target sensitive cells is to select leukemic clones which harbor disrupted transcription factors. CBFalpha and CBFbeta are core-binding proteins which have been identified as transcription regulators of hematopoietic genes and shown to be altered in numerous leukemias. In M2 AML, the t(8;21) translocation, CBFalpha (AML1) is altered and produced as the AML1-ETO fusion protein. The fusion protein blocks transcription and differentiation mediated by G-CSF. Interestingly, AML1-ETO leukemic cell lines are sensitive to numerous cytokines in vitro and can be induced to differentiate in the presence of G-CSF and PMA. MATERIALS AND

METHODS:

As in the APL differentiation model, primary culture provides a useful tool for therapeutic screening of differentiation inducers, we analysed the in vitro sensitivity of 10 fresh M2 AML t(8;21) leukemic samples to G-CSF and the functionality of G-CSF intracellular pathways. In vitro data were compared with in vivo data from four patients treated with rhG-CSF at the dosage of 5 microg/kg/day i.v. for two to three weeks before the initiation of AML induction chemotherapy and immunophenotypic analysis performed weekly to monitor in vivo differentiation.

RESULTS:

In vitro, an increase in CD34+ cells expressing differentiation antigens (CD11b, CD13 or CD15) was noted along with a decrease of immature CD34+/differentiation antigen negative cells. After two weeks of a daily rhG-CSF administration in vivo, a significant, albeit transient, decrease of blast count was achieved, concomitant with an increase in differentiated leukemic cells suggesting that in vivo differentiation occurs. Fresh t(8;21) leukemic cells possess functional G-CSF signaling pathways as normal activity and kinetics of STAT1 and STAT3 binding was observed. Furthermore, differentiation induction leads to a subsequent degradation of the AML1-ETO oncoprotein.

CONCLUSION:

The data presented here supports the claim that G-CSF can induce in vitro and in vivo differentiation of M2 AML t(8;21) cells.
Subject(s)
Search on Google
Collection: 01-internacional Health context: 6_ODS3_enfermedades_notrasmisibles Database: MEDLINE Main subject: Transcription Factors / Translocation, Genetic / Chromosomes, Human, Pair 8 / Chromosomes, Human, Pair 21 / Leukemia, Myeloid, Acute / Oncogene Proteins, Fusion / Granulocyte Colony-Stimulating Factor / Receptors, Granulocyte Colony-Stimulating Factor / Neoplasm Proteins Type of study: Prognostic_studies Limits: Humans Language: En Journal: Hematol J Year: 2000 Document type: Article
Search on Google
Collection: 01-internacional Health context: 6_ODS3_enfermedades_notrasmisibles Database: MEDLINE Main subject: Transcription Factors / Translocation, Genetic / Chromosomes, Human, Pair 8 / Chromosomes, Human, Pair 21 / Leukemia, Myeloid, Acute / Oncogene Proteins, Fusion / Granulocyte Colony-Stimulating Factor / Receptors, Granulocyte Colony-Stimulating Factor / Neoplasm Proteins Type of study: Prognostic_studies Limits: Humans Language: En Journal: Hematol J Year: 2000 Document type: Article